Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.57 |
| ▸ | FEN1 | P39748 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388180 | 0.88 | ERCC5 (0.53) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL7388254 | 0.88 | ERCC5 (0.53) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL5158762 | 0.85 | ERCC5 (0.57) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL69498 | 0.85 | ERCC5 (0.61) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL29419340 | 0.85 | ERCC5 (0.61) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL3317470 | 0.83 | ERCC5 (0.59) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL2598234 | 0.83 | ERCC5 (0.59) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL10792354 | 0.83 | PARP1 (0.60) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL27563465 | 0.82 | ERCC5 (0.54) | ERCC5FEN1PARP1MEN1KMT2A | |
| SCHEMBL5539091 | 0.81 | ERCC5 (0.57) | ERCC5FEN1PARP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558686-B | Preparation method of bupropion hydrochloride | 绍兴文理学院元培学院 | 2020-11-06 | — | — | CN | disclosed |
| CN-108558686-A | A kind of preparation method of BUPROPIONE HCl | 绍兴文理学院元培学院 | 2018-09-21 | — | — | CN | disclosed |
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| EP-1993525-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102008-A1 | THE USE OF BETA-AMINOALCOHOLS IN THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |
| US-4025558-A | SPIRO(CYCLOHEXANE-1,1*(2'H)-NAPHTHALENE); BENZOSPIRAN DERIVATIVES; CNS DEPRESSANTS, LOWERS BLOOD PRESSURE | THE UPJOHN COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-4010201-A | AMINOBENZOSPIRANS, CENTRAL NERVOUS SYSTEM DEPRESSANT, HYPOTENSIVE | THE UPJOHN COMPANY (US) | 1977-03-01 | — | — | US | disclosed |
| US-3932425-A | CNS DEPRESSANT, BLOOD PRESSURE LOWERING | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, HRH2 | ERCC5 4175/4885FEN1 4842/4885PARP1 3752/4885 |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, NR1H2 | ERCC5 3974/4885FEN1 4815/4885PARP1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.